Enquire

Enrich your medicines pipeline

The research partner that creates innovative solutions, builds dynamic relationships and enriches your medicines pipeline across a range of human diseases

Our Services

Graphic showing vision and mission icons

Our Vision and Mission

Our strong vision and mission statements underpin everything we do at Domainex. They guide our team with a common purpose that ensures we deliver outstanding drug discovery services to our clients.

Integrated drug discovery Services

We offer a truly integrated approach for a faster route to drug discovery. Our dedicated experts will work collaboratively with you to provide tailored scientific solutions.

Cogs Graphic

King’s Award for Enterprise: International Trade 2023 winner

Domainex has been awarded a King’s Award for Enterprise recognising the company’s outstanding growth in international trade. The award is testament to the innovation, customer focus and dedication of the whole team.

Offerings

Research Phases

Therapeutic Areas

Target Classes

Approaches & Techniques

Case Studies

Adenosine A2a receptor: Novel Biophysical Fragment Screening using Polymer-Encapsulated Nanodiscs

Novel biophysical fragment screening using polymer-encapsulated nanodiscs and spectral shift technology for the Adenosine A2a receptor. View more

MAP4K4: Kinase inhibitors for cardioprotection following heart attacks

Domainex designed novel, potent, highly selective, small-molecule inhibitors of MAP4K4, with potential cardioprotective drug properties. View more

Tankyrase: Inhibitors for the treatment of solid tumours

Domainex employed its LeadBuilder virtual screening technology to identify tankyrase inhibitors from which pre-clinical development candidates emerged. View more

Der p 1: Protease Inhibitors for the treatment of asthma

Domainex collaborated with St George’s University London & the University of Manchester on a programme of drug discovery which led to the successfully nomination of a candidate drug. View more

TBK1/IKKε: Kinase inhibitors for the treatment of interferonopathies

Domainex identified a drug candidate DMXD-011, a first-in-class small-molecule orally bioavailable inhibitor of TBK1/IKKε View more

FLIPP-FADD: PPI inhibitors for the treatment of solid tumours

Domainex and Queen's University Belfast have discovered the world’s first inhibitors of FLIP-FADD and produced viable leads for drug candidate selection View more

Ras: PPI inhibitors for the treatment of cancer

Domainex used its extensive experience of fragment- & structure-based drug design to develop a lead molecule with strong binding to RAS, an oncology target. View more

G9a: Lysine Methyltransferase Inhibitors for the Treatment of Cancer

Starting from a LeadBuilder screen we identified novel potent inhibitors of G9a, which have potential to be developed as treatments for a range of solid tumours. View more

News

Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services

Domainex included in inaugural special report from the Financial Times recognising Europe’s Long-Term Growth Champions

Synthesis in Review: Boryl Radical Mediated Halogen Atom Transfer for Versatile C-C Bond Formation and Stereospecific Alkenylidene Homologation of Organoboronates

Events

Nov 10 32nd Protein Structure Determination in Industry Conference (PSDI 2024)

Nov 11 Webinar | Let’s get biophysical: Overcoming challenges in drug discovery with biophysics

Dec 9 Webinar | The reemergence of covalent compounds: Domainex’s approach to covalent fragment screening

LinkedIn Posts

Start your next project with Domainex

Contact one of our experts today